Pangramin SLIT HDM mix.
ApprovedBiologic
Pangramin SLIT HDM mix. is one of 45 biologic programs targeting Rhinitis. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Pangramin SLIT HDM mix.
AALK-Abelló A/S
Approved
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Atrovent
Boehringer IngelheimPreclinical
Arcoxia
NovartisPreclinical
Symbicort
AstraZenecaPreclinical
Aciphex
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pangramin SLIT HDM mix.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Approved[1]
- Company
- AALK-Abelló A/S